Very bullish indeed that the main shareholder buy at this stage. Big endorsement of Peter Cockcroft.This also gives me full confidence on a positive outcome on the debt restructuring.
MSB Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%